Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid.
We investigated the effect of chenodeoxycholic acid on cerebrospinal fluid sterol and protein composition in six patients with cerebrotendinous xanthomatosis, a progressive neurologic disease, and in 11 control subjects. In the cerebrospinal fluid from the controls, the mean (+/- SD) levels of cholesterol and cholestanol were 400 +/- 300 and 4 +/- 7 micrograms per deciliter, respectively. The levels were almost 1.5 and 20 times higher in cerebrospinal fluid from untreated patients with cerebrotendinous xanthomatosis. Cholestanol levels were also markedly elevated in the plasma of untreated patients, but their plasma cholesterol levels (215 +/- 61 mg per deciliter) were not different from control values. Treatment with chenodeoxycholic acid reduced cerebrospinal fluid cholesterol by 34 percent and cholestanol threefold. Plasma cholestanol levels also decreased sharply. Normal cerebrospinal fluid contained small quantities of albumin, apolipoproteins, and lecithin:cholesterol acyltransferase. In cerebrospinal fluid from untreated patients with cerebrotendinous xanthomatosis, immunoreactive apolipoprotein B or apolipoprotein B fragment was increased about 100-fold and albumin about 3.5-fold; apolipoprotein AI, apolipoprotein D, and lecithin:cholesterol acyltransferase were 1.5 to 3 times more concentrated. Apolipoprotein AIV and apolipoprotein E concentrations were comparable to those in controls, and apolipoprotein AII was considerably decreased. During treatment, the concentrations of albumin and apolipoproteins AI and B declined. These results suggest that increased cerebrospinal fluid sterols are derived from plasma lipoproteins by means of a defective blood-brain barrier in patients with cerebrotendinous xanthomatosis. Therapy with chenodeoxycholic acid reestablished selective permeability of the blood-brain barrier and normalized the concentrations of sterol and apolipoprotein in the cerebrospinal fluid.
D000418:Albumins / Q000134:cerebrospinal fluid; D001053:Apolipoproteins / Q000134:cerebrospinal fluid; D001055:Apolipoproteins B / Q000134:cerebrospinal fluid*; D001812:Blood-Brain Barrier / Q000187:drug effects; D001928:Brain Diseases, Metabolic / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D002635:Chenodeoxycholic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D004083:Cholestanol / Q000097:blood / Q000134:cerebrospinal fluid*; D002784:Cholesterol / Q000031:analogs & derivatives* / Q000134:cerebrospinal fluid; D005260:Female; D006801:Humans; D008297:Male; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000134:cerebrospinal fluid; D013710:Tendons; D014973:Xanthomatosis / Q000134:cerebrospinal fluid* / Q000188:drug therapy
D000418:Albumins; D001053:Apolipoproteins; D001055:Apolipoproteins B; D002635:Chenodeoxycholic Acid; D004083:Cholestanol; D002784:Cholesterol; D007862:Phosphatidylcholine-Sterol O-Acyltransferase